References
- Laurell C, Eriksson, S. The electrophorectic alpha-1 globulin pattern of serum in alpha 1-antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15:132–140.
- Fagerhol MK, Laurell CB. The polymorphism of ìprealbuminsî and alpha-1 antitrypsin in human sera. Clin Chim Acta 1967; 16(2):199–203.
- Turino GM, Senior RM, Garg GD, Keller S, Levi MM, Mandl I. Serum elastase inhibitor deficiency and alpha-1 antitrypsin deficiency in patients with obstructive emphysema. Science 1969; 165:709–711.
- Lomas DA, Evans DL, Finch JT, The mechanism of Z alpha-1 antitrypsin accumulation in the liver. Nature 1992; 357(6379):605–607.
- The Alpha-1 Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 1998; 158(1):49–59.
- Seersholm N, Does alpha-1 antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10(10):2260–2263.
- Wencker M, Longitudinal follow-up of patients with alpha-1 protease inhibitor deficiency before and during therapy with IV alpha-1 protease inhibitor. Chest 2001; 119(3):737–744.
- Chapman KR, Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 2009; 6(3):177–184.
- Bernspang E, CT lung densitometry in young adults with alpha-1 antitrypsin deficiency. Respir Med 2011; 105(1):74–79.
- Tanash HA, Survival in severe alpha-1 antitrypsin deficiency (PiZZ). Respir Res 2010; 11:44
- Dawkins PA, Rate of progression of lung function impairment in alpha-1 antitrypsin deficiency. Eur Respir J 2009; 33(6):1338–1344.
- Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in alpha-1 antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001; 164(10 Pt 1):1805–1809.
- Needham M, Stockley RA. Exacerbations in alpha-1 antitrypsin deficiency. Eur Respir J 2005; 25(6):992–1000.
- Vijayasaratha K, Stockley RA. Reported and unreported exacerbations of COPD: Analysis by diary cards. Chest 2008; 133:34–41.
- Parr DG, Validation of computed tomographic lung densitometry for monitoring emphysema in alpha-1 antitrypsin deficiency. Thorax 2006; 61(6):485–490.
- Dawkins PA, Predictors of mortality in alpha-1 antitrypsin deficiency. Thorax 2003; 58(12):1020–1026.
- Dirksen A, A randomized clinical trial of alpha-1 antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160 (5 Pt 1):1468–1472.
- Dirksen A, Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33(6):1345–1353.
- World Health Organization Alpha-1 antitrypsin deficiency: memorandum from a WHO meeting, available on their web site. Bull World Health Organ 1997; 75(5):397–415.
- Carter RI, The fibrinogen cleavage product alpha-Val360, a specific marker of neutrophil elastase activity in vivo. Thorax 2011; 66(8):686–691.